The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Company profile
Ticker
BMY, BMYMP, CELG-RI
Exchange
Website
CEO
Giovanni Caforio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1096271 BC ULC • 345 Park LLC • 9643435 Canada Inc. • Abraxis BioScience Australia Pty Ltd. • Abraxis BioScience International Holding Company, Inc. • Abraxis BioScience Puerto Rico, LLC • Abraxis BioScience, Inc. • Abraxis BioScience, LLC • AbVitro LLC • Acetylon Pharmaceuticals, Inc. ...
IRS number
220790350
BMY stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Other Events
10 Aug 23
10-Q
2023 Q2
Quarterly report
27 Jul 23
8-K
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
27 Jul 23
8-K
Departure of Directors or Certain Officers
4 May 23
10-Q
2023 Q1
Quarterly report
27 Apr 23
8-K
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
27 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
8-K
Bristol Myers Squibb Announces Leadership Transition Plan
26 Apr 23
DEFA14A
Additional proxy soliciting materials
10 Apr 23
ARS
2022 FY
Annual report to shareholders
23 Mar 23
Transcripts
BMY
Earnings call transcript
2023 Q2
27 Jul 23
BMY
Earnings call transcript
2023 Q1
27 Apr 23
BMY
Earnings call transcript
2022 Q4
2 Feb 23
BMY
Earnings call transcript
2022 Q3
26 Oct 22
BMY
Earnings call transcript
2022 Q2
27 Jul 22
BMY
Earnings call transcript
2022 Q1
29 Apr 22
BMY
Earnings call transcript
2021 Q4
4 Feb 22
BMY
Earnings call transcript
2021 Q3
27 Oct 21
BMY
Earnings call transcript
2021 Q2
28 Jul 21
BMY
Earnings call transcript
2021 Q1
29 Apr 21
Latest ownership filings
4
Ann Powell
28 Aug 23
144
Notice of proposed sale of securities
24 Aug 23
4
Robert M Plenge
7 Aug 23
144
Notice of proposed sale of securities
3 Aug 23
3
Robert M Plenge
5 Jul 23
4
PHYLLIS R YALE
5 Jul 23
4
Gerald L Storch
5 Jul 23
4
Theodore R. Samuels II
5 Jul 23
4
Derica W Rice
5 Jul 23
4
Julia A Haller
5 Jul 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 8.43 bn | 8.43 bn | 8.43 bn | 8.43 bn | 8.43 bn | 8.43 bn |
| Cash burn (monthly) | 207.67 mm | 211.25 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 604.39 mm | 614.82 mm | n/a | n/a | n/a | n/a |
| Cash remaining | 7.82 bn | 7.81 bn | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 37.7 | 37.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q2 2023
74.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2344 |
| Opened positions | 113 |
| Closed positions | 233 |
| Increased positions | 890 |
| Reduced positions | 1012 |
| 13F shares | Current |
|---|---|
| Total value | 99.02 tn |
| Total shares | 1.55 bn |
| Total puts | 13.52 mm |
| Total calls | 18.01 mm |
| Total put/call ratio | 0.8 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 203.74 mm | $13.03 tn |
| BLK Blackrock | 172.67 mm | $11.04 tn |
| JPM JPMorgan Chase & Co. | 103.31 mm | $6.61 tn |
| STT State Street | 92.57 mm | $5.92 tn |
| Capital International Investors | 69.30 mm | $4.43 tn |
| FMR | 46.75 mm | $2.99 tn |
| Geode Capital Management | 39.03 mm | $2.49 tn |
| MS Morgan Stanley | 34.97 mm | $2.24 tn |
| BAC Bank Of America | 29.10 mm | $1.86 tn |
| AMP Ameriprise Financial | 26.74 mm | $1.71 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 Aug 23 | Ann Powell | Common Stock, $0.10 par value | Sell | Dispose S | No | No | 61.25 | 17,986 | 1.10 mm | 27,868.088 |
| 3 Aug 23 | Plenge Robert M | Common Stock, $0.10 par value | Sell | Dispose S | No | No | 61.14 | 732 | 44.75 k | 6,584 |
| 3 Jun 23 | Adam Lenkowsky | Common Stock, $0.10 par value | Payment of exercise | Dispose F | No | No | 65.66 | 551 | 36.18 k | 526 |
| 3 Jun 23 | Adam Lenkowsky | Common Stock, $0.10 par value | Option exercise | Acquire M | No | No | 0 | 1,077 | 0.00 | 1,077 |
| 3 Jun 23 | Adam Lenkowsky | RSU Common Stock, $0.10 par value | Option exercise | Dispose M | No | No | 0 | 1,077 | 0.00 | 0 |
| 3 May 23 | Rupert Vessey | Common Stock, $0.10 par value | Sell | Dispose S | No | No | 67.06 | 50,385 | 3.38 mm | 47,751 |
| 2 May 23 | Sharon Greenlees | Common Stock, $0.10 par value | Payment of exercise | Dispose F | No | No | 68.1 | 119 | 8.10 k | 609 |
| 2 May 23 | Sharon Greenlees | Common Stock, $0.10 par value | Option exercise | Acquire M | No | No | 0 | 328 | 0.00 | 728 |
| 2 May 23 | Sharon Greenlees | Common Stock, $0.10 par value | Payment of exercise | Dispose F | No | No | 68.1 | 227 | 15.46 k | 400 |
| 2 May 23 | Sharon Greenlees | Common Stock, $0.10 par value | Other | Dispose J | No | No | 0 | 62 | 0.00 | 627 |
News
Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study
22 Sep 23
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
18 Sep 23
Looking Into Bristol-Myers Squibb's Recent Short Interest
18 Sep 23
Samsung Biologics Announced Expanded Strategic Agreement With Bristol Myers Squibb To Manufacture An Antibody Cancer Drug Substance
17 Sep 23
10 Health Care Stocks Whale Activity In Today's Session
15 Sep 23
Press releases
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
26 Sep 23
Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise
26 Sep 23
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
26 Sep 23
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
22 Sep 23
Bristol Myers Squibb Announces Dividend
20 Sep 23